Polymorphisms influencing prostate-specific antigen concentration may bias genome-wide association studies on prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 1, 2015, Pages 88-93

  Dluzniewski, Paul J ^a   Xu, Jianfeng ^b   Ruczinski, Ingo ^a   Isaacs, William B ^c,d   Platz, Elizabeth A ^a,c,d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; COHORT ANALYSIS; GENETIC POLYMORPHISM; GENETICS; GENOME-WIDE ASSOCIATION STUDY; METABOLISM; PROCEDURES; PROSTATE TUMOR;

AGED; COHORT STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84921027475     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0863     Document Type: Article

References (30)

1. Kim ST, Cheng Y, Hsu FC, Jin T, Kader AK, Zheng SL, et al. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation. Prostate 2010; 70:1729-38.
2. Liu H, Wang B, Han C. Meta-analysis of genome-wide and replication association studies on prostate cancer. Prostate 2011;71: 209-24.
3. Wiklund F, Zheng SL, Sun J, Adami HO, Lilja H, Hsu FC, et al. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate 2009;69:419-27.
4. Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, Arinbjarnarson S, et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2010;2: 62ra92.
5. Ahn J, Berndt SI, Wacholder S, Kraft P, Kibel AS, Yeager M, et al. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet 2008;40:1032-4.
6. Cramer SD, Chang BL, Rao A, Hawkins GA, Zheng SL, Wade WN, et al. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst 2003;95:1044-53.
7. Xu J, Isaacs SD, Sun J, Li G, Wiley KE, Zhu Y, et al. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res 2008;14:5819-24.
8. Xue WM, Coetzee GA, Ross RK, Irvine R, Kolonel L, Henderson BE, et al. Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2001;10:575-9.
9. National Cancer Institute: PDQ(R) Genetics of Prostate Cancer. Bethesda, MD: National Cancer Institute. Date last modified 10/30/ 2014. Available at: http://cancer.gov/cancertopics/pdq/genetics/prostate/HealthProfessional. Table 4. Accessed 06/29/2014.
10. Xu J, Sun J, Zheng SL. Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian J Androl 2013;15:314-22.
11. Aly M, Wiklund F, Xu J, Isaacs WB, Eklund M, D'Amato M, et al. Polygenic risk score improves prostate cancer risk prediction: results from the stockholm-1 cohort study. Eur Urol 2011;60:21-8.
12. Hsu FC, Sun J, Zhu Y, Kim ST, Jin T, Zhang Z, et al. Comparison of two methods for estimating absolute risk of prostate cancer based on single nucleotide polymorphisms and family history. Cancer Epidemiol Biomarkers Prev 2010;19:1083-8.
13. Table 1. Annual Estimates of the Resident Population by Sex and Five-Year Age Groups for the United States: April 1, 2000 to July 1, 2009 (NCEST2009-01). Source: U.S. Census Bureau, Population Division. Release Date: June 2010. [cited 2011 March]. Available from: http://www.census.gov/popest/data/historical/2000s/vintage-2009/index.html.
14. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
15. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. [cited 2011 March]. Available at: http://www.cdc.gov/nchs/nhanes.htm.
16. Guzzo TJ, Dluzniewski P, Orosco R, Platz EA, Partin AW, Han M. Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology 2010;76:553-7.
17. Bansal A, Murray DK, Wu JT, Stephenson RA, Middleton RG, Meikle AW. Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twins. J Clin Endocrinol Metab 2000;85: 1272-6.
18. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40:316-21.
19. Pal P, Xi H, Sun G, Kaushal R, Meeks JJ, Thaxton CS, et al. Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin. Hum Genet 2007;122: 251-9.
20. Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA, Ingles SA. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 2000;60: 839-41.
21. Xu J, Meyers DA, Sterling DA, Zheng SL, Catalona WJ, Cramer SD, et al. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol Biomarkers Prev 2002;11:664-9.
22. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, et al. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate 2002;53:88-94.
23. Schatzl G, Marberger M, Remzi M, Grosser P, Unterlechner J, Haidinger G, et al. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer. Urology 2005;65:1141-5.
24. Barry MJ. Screening for prostate cancer-the controversy that refuses to die. N Engl J Med 2009;360:1351-4.
25. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
26. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
27. Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 2007;67:312-29.
28. Ferguson JP, Cho JH, Yang C, Zhao H. Empirical Bayes correction for the Winner's Curse in genetic association studies. Genet Epidemiol 2013; 37:60-8.
29. Zhong H, Prentice RL. Correcting "winner's curse" in odds ratios from genomewide association findings for major complex human diseases. Genet Epidemiol 2010;34:78-91.
30. Zollner S, Pritchard JK. Overcoming the winner's curse: estimating penetrance parameters from case-control data. Am J Hum Genet 2007; 80:605-15.